INDIVIDUAL BIOEQUIVALENCE TESTING TO REQUIRE "FEWER TOTAL ADMINISTRATIONS" FOR HIGH-VARIABILITY DRUGS THAN CURRENT APPROACH, FDA TELLS ADVISORY CMTE.
Executive Summary
FDA's proposed standards for "individual" bioequivalence testing would require less testing by generic companies for high-variability drugs than FDA's current standards, the agency told the Advisory Committee for Pharmaceutical Science Aug. 15.